English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18074/20272 (89%)
造訪人次 : 4072721      線上人數 : 920
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/30991


    標題: The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer
    作者: Chang, Wei-Ting
    Shih, Jhih-Yuan
    Feng, Yin-Hsun
    Chiang, Chun-Yen
    Kuo, Yu Hsuan
    Chen, Wei-Yu
    Wu, Hong-Chang
    Cheng, Juei-Tang
    Wang, Jhi-Joung
    Chen, Zhih-Cherng
    貢獻者: Chi Mei Med Ctr, Div Cardiol, Dept Internal Med
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    Chi Mei Med Ctr, Dept Internal Med, Div Oncol
    Chi Mei Med Ctr, Dept Med Res
    Chia Nan Univ Pharm & Sci, Dept Pharm
    關鍵字: Dyspnea
    Epirubicin
    Right ventricle
    Speckle-tracking echocardiography
    dysfunction
    日期: 2016-09
    上傳時間: 2018-01-18 11:39:23 (UTC+8)
    出版者: Taiwan Soc Cardiology
    摘要: Background: As cancer therapies have improved, patient life spans have been extended but quality of life has been threatened by chemotherapy induced cardiotoxicity. Most cardiac complications remain unobserved until specific symptoms develop. Speckle-tracking echocardiography is a sensitive imaging modality in detecting early occult myocardial dysfunction. Methods: A total number of 35 patients newly diagnosed with breast cancer and preparing for epirubicin therapy were prospectively recruited. Echocardiography, including speckle-tracking echocardiography, was performed sequentially at baseline (T1), after the first cycle (T2) and after the third cycle (T3) of epirubicin. At each visit, the severity of dyspnea was evaluated by the assessment scale. Results: Compared with the baseline, right ventricular longitudinal strain (RVLS_FW) at T2 significantly declined (-22.49 +/- 4.97 vs. -18.48 +/- 4.46, p = 0.001), which was also positively associated with the development of dyspnea (R-2 = 0.8, p = 0.01). At T3, both the left ventricular global longitudinal strain and RVLS_FW were significantly impaired (-21.4 +/- 4.12 vs.-16.94 +/- 6.81%; -22.49 +/- 4.97 vs. -16.86 +/- 7.27%, p = 0.01; 0.001, respectively). Also, the accumulating dose of epirubicin positively correlated with the development of dyspnea (R-2 = 0.38, p = 0.04) and the decline of RVLS_FW (R-2 = 0.53, p = 0.02). Notably, compared with the other echocardiographic parameters only RVLS_FW at the early stage (T2) significantly correlated with the development of dyspnea (odds ratio: 1.84, 95% confidence interval: 1.22-2.78, p = 0.04). Conclusions: RVLS_FW sensitively predicts dyspnea development in breast cancer patients receiving epirubicin therapy. However, larger scale studies are required to validate its role in long-term patient survival.
    關聯: Acta Cardiologica Sinica, v.32 n.5, pp.550-559
    顯示於類別:[藥學系(所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    30991.pdf544KbAdobe PDF367檢視/開啟
    index.html0KbHTML1210檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋